T. Rowe Price Associates’s Climb Bio CLYM Stock Holding History

T. Rowe Price Associates’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27.7M	Buy	2,127,281 +210,313	+11%	+$2.17M	﹤0.01%	1058
2026 Q1	$13.1M	Sell	1,916,968 -6,671	-0.3%	-$38.5K	﹤0.01%	1148
2025 Q4	$7.7M	Buy	1,923,639 +1,396,722	+265%	+$3.35M	﹤0.01%	1289
2025 Q3	$1.06M	Sell	526,917 -21,048	-4%	-$39.1K	﹤0.01%	2039
2025 Q2	$680K	Sell	547,965 -37,763	-6%	-$47K	﹤0.01%	2157
2025 Q1	$716K	Sell	585,728 -42,922	-7%	-$69.6K	﹤0.01%	2112
2024 Q4	$1.13M	Sell	628,650 -43,916	-7%	-$159K	﹤0.01%	1912
2024 Q3	$3.42M	Buy	+672,566	New	+$4.76M	﹤0.01%	1414

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

T. Rowe Price Associates's CLYM Position: Q2 2026 in Review

T. Rowe Price Associates increased its Climb Bio (CLYM) stake by 11% in Q2 2026, buying an estimated $2.17M and bringing the position to 2,127,281 shares worth $27.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1058.

T. Rowe Price Associates first reported a position in CLYM in Q3 2024 and has held it in 8 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

T. Rowe Price Associates held 2,127,281 shares of Climb Bio worth $27.7M as of Q2 2026.
T. Rowe Price Associates bought 210,313 Climb Bio shares in Q2 2026, an estimated $2.17M.
Climb Bio made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1058 holding.
T. Rowe Price Associates first reported a position in Climb Bio in Q3 2024 and has held it in 8 quarters since.
109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.